Company Overview
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
Why Investors Should Care
Trades at a P/E of 1.1, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.19.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -57.50% |
| 6 Months: | -33.33% |
| 3 Months: | +39.73% |
| 1 Month: | +13.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)44.72 · Neutral
P/E of 1.08 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 74.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DWTX Dogwood Therapeutics, Inc. PHARMA | 2.04 | 1.08 | $69.34M | 0.00% | -32.11% | -47.77% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -382.55K | -538.38K | -2.66M | -3.06M | -4.28M | -4.11M | -3.96M | -3.67M | -2.59M | -1.56M | -1.48M | -1.27M | -1.31M | -1.07M | -2.30M | -4.43M | -3.92M | -15.81M | -5.08M |
| Net Income | -466.55K | -654.59K | -2.72M | -3.06M | -4.28M | -4.11M | -3.96M | -3.67M | -2.58M | -1.52M | -1.44M | -1.24M | -1.29M | -1.05M | -2.28M | -10.92M | -3.81M | -15.74M | -4.99M |
| Diluted EPS | - | - | - | -0.37 | -0.51 | -0.49 | -0.48 | -0.44 | -0.28 | -0.08 | -0.08 | -1.62 | -1.68 | -1.15 | -2.05 | -8.45 | -1.99 | -8.20 | -0.15 |
| R&D Expense | 30.54K | 23.32K | 108.09K | 1.71M | 3.21M | 2.96M | 2.77M | 2.41M | 1.62M | 497.71K | 557.84K | 374.20K | 343.72K | 336.08K | 535.16K | 2.44M | 2.57M | 14.52M | 2.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -10.01M | -15.64M | -12.32M | -5.45M | -12.23M | -27.97M |
| Net Income | -10.35M | -15.96M | -12.25M | -5.30M | -12.35M | -34.26M |
| Diluted EPS | -2.10 | -1.92 | -1.11 | -7.05 | -12.52 | -7.13 |
| R&D Expense | 194.01K | 10.80M | 8.07M | 1.73M | 3.53M | 21.87M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 31.47M | 15.78M | 8.37M | 4.17M | 94.31M | 90.17M |
| Total Equity | -5.02M | 29.94M | 14.50M | 7.33M | 3.81M | -10.12M | 74.90M |
| Cash & Equivalents | - | 29.80M | 14.01M | 7.03M | 3.32M | 14.85M | 6.52M |
| Total Liabilities | - | 1.53M | 1.28M | 1.04M | 358.55K | 30.03M | 15.27M |
| Current Liabilities | - | 1.53M | 1.28M | 1.04M | 358.55K | 3.18M | 3.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.90M | -15.69M | -11.47M | -4.87M | -8.79M | -15.62M |
| Investing Cash Flow | - | - | - | - | 3.76M | - |
| Financing Cash Flow | 33.38M | -97.60K | 4.49M | 1.16M | 16.70M | 7.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -34.6% | -110.1% | -167.2% | -139.1% | 122.0% | -45.7% |
| ROCE % | -33.4% | -107.9% | -168.1% | -143.1% | -13.4% | -32.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 9.22% | 3.13M | $5.29M |
| 2 | Millennium Management Llc | 1.01% | 341.81K | $577.66K |
| 3 | Vanguard Capital Management LLC | 0.39% | 132.15K | $223.34K |
| 4 | Geode Capital Management, LLC | 0.26% | 88.30K | $149.22K |
| 5 | Vanguard Fiduciary Trust Co | 0.18% | 62.74K | $106.02K |
| 6 | Blackrock Inc. | 0.08% | 28.55K | $48.24K |
| 7 | Northern Trust Corporation | 0.07% | 23.78K | $40.19K |
| 8 | Citadel Advisors Llc | 0.03% | 11.74K | $19.84K |
| 9 | Tower Research Capital LLC (TRC) | 0.01% | 3.09K | $5.23K |
| 10 | Morgan Stanley | 0.01% | 2.22K | $3.75K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DWTX
Dogwood Reports 4.5% Early Termination Rate Among First 200 Patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZm1zcDB6cjlNNWVMS3lKMHlwWktpRkJQRTJvRHppbEdLcU9rRjk5SEUtbGJ0azFsNVZXbTExc25wUVRGWE1tT21KcWc0MGpsaXlvOTdtdDZzcU5aVjV6czM1SGdRbDI4b3JmMjFqbnIxU3phUEU0THA3dm05d0NGa00taWNGU2ZZcnRIeG…
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSGcxQ2t2MTgwV0ZHUWlZc193anZZQnZqZ21VaUp2TnBkZ2hSdWtWQi1fVkVkNlNTQ1lmakhTWVBhTFhNXzdNY0plOHlPWW9HQWcwODFFLTFsMTZvdmlaUzd6T2ctc0dQZEdLSmlaamw3N0xLQlFWQTg0R1FiT2VyaEo1ZWRwdUZ3SE52ZT…
Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1XVWFCSHFJdld4cDYzMEdBRzBGNWVScHgtLUgtQTRINE16b0tmdlBlWE8wemNxVXM3WHFXTHVHRzRXb0ZudExaVWFHcElycUdGWHhBYUNB?oc=5" target="_blank">Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Pri…
DWTX - Dogwood Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1UVFRkRDFoekMtSmxsUmxDbkxrNTlsTlpQMTIyVG9iczR0OC16NlFvV3NtRVVzT2swOEktN2EtNWR6MTdHTFE?oc=5" target="_blank">DWTX - Dogwood Therapeutics Inc Stock Price and Quote</a> <fo…
Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNb1I2TnZONGFqbWRXYjl6ajdHMnI2dm50OGd4SGVtNUdsSmVCTXRMdC0xU1NMX044Y2t3NUg0aFBjWThTUVFnQUkzUUJnTjRUN3VhNWhwdDNQNmdUMDNodk5Pc05MRFZ6QzBXZ0VIZlFPTDRFXzB3OHhZSktvekZWTi01SHA0WXJObjVKY2…
DWTX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1IcEJWcXlfUmhsNzdaRk1fQzJKVE1mUVozaDluVzJIS3pOZEZxVmkyT2R2SlA3SW8tY0hTVGQ1R3BkTGFwa1U5STc3SmZCTHpRXzRhbi1PdDZIWGRINDlqaGpZWmNxeWlVN0EwUE9PdWE2ZHZqd3J1ZlVB?oc=5" target="_blank">DWT…
DWTX — Frequently Asked Questions
What is the current share price of Dogwood Therapeutics, Inc. (DWTX)?
As of 2026-09-19 21:16 PDT, Dogwood Therapeutics, Inc. (DWTX) trades at $2.04 on NasdaqCM. Its 52-week range is $1.34 to $7.91.
What is the market capitalisation of DWTX?
Dogwood Therapeutics, Inc. (DWTX) has a market capitalisation of $69.34M on NasdaqCM.
What is the P/E ratio of DWTX?
DWTX trades at a trailing price-to-earnings (P/E) ratio of 1.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.95.
What is the return on equity (ROE) of DWTX?
DWTX has a return on equity (ROE) of -47.77%. Its return on capital employed (ROCE) is -32.11%.
Is DWTX a good stock to buy?
This page provides a data-driven analysis of Dogwood Therapeutics, Inc. (DWTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.